Program
zibotentan
Also written as “ZD4054”, “Zibotentan” and “Zibotentan/Dapagliflozin”.
Its studies are mostly in Prostatic Neoplasms · Renal Insufficiency, Chronic · Liver Cirrhosis · Kidney Diseases · Renal Insufficiency, led by AstraZeneca.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 232 open or running | phase 3since Nov 2, 2007 | Mar 3, 2003 | Feb 18, 2027phase 3 · NCT06087835 |
- Named in AstraZeneca’s own pipeline as
zibotentan/dapagliflozin
, phase 3, as of Oct 30, 2026 (source).
Also a collaborator on its studies: parexel and pra-health-sciences.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 7 studies since Mar 3, 2003.
- Jul 1, 20083 phase 1 studiesNCT00710047, NCT00709553, NCT00713791
- Sep 2, 2008Phase 2 study in Carcinoma, Non-Small-Cell LungNCT00745875 · 66 enrolled · Bulgaria, Czech Republic, France and more
- Jun 25, 2009Phase 2 study in NeoplasmsNCT00929162 · 120 enrolled · Germany, Italy
- Oct 19, 2009Phase 1 study in Advanced Solid MalignanciesNCT00997945 · 15 enrolled · China
- Jan 25, 2021Phase 2 study in Renal Insufficiency, ChronicNCT04724837 · 542 enrolled · United States, Argentina, Australia and more
- Jul 28, 2021Phase 1 study in Renal Insufficiency, ChronicNCT04991571 · 27 enrolled · United States
- Oct 11, 2021Phase 1 study in Renal InsufficiencyNCT05112419 · 12 enrolled · Bulgaria
- Aug 16, 2022Phase 1 study in Renal Insufficiency, ChronicNCT05505162 · 24 enrolled · United States
- Aug 24, 2022Phase 2 study in Liver CirrhosisNCT05516498 · 205 enrolled · United States, Australia, Austria and more
- Oct 4, 2023Phase 3 study in Kidney DiseasesNCT06087835 · 1,835 enrolled · United States, Argentina, Australia and more
- Feb 2, 2024Phase 2 study in Liver CirrhosisNCT06269484 · 73 enrolled · United States, Australia, Belgium and more
- Nov 29, 2024Phase 1 study in Liver CirrhosisNCT06715670 · 30 enrolled · United States
- Apr 17, 2025Phase 2 study in Kidney DiseasesNCT06942910 · 224 enrolled · Russia
- Feb 5, 2026Phase 1 study in Renal Insufficiency, ChronicNCT07404137 · 26 enrolled · United States
Ahead
- Feb 18, 2027Primary completion: phase 3 study in Kidney DiseasesNCT06087835
TargetBeta
“An orally available selective antagonist of the endothelin-A (ET-A) receptor with potential antineoplastic activity. Zibotentan binds selectively to the ET-A receptor, thereby inhibiting endothelin-mediated mechanisms that promote tumor cell proliferation.”NCIt, read by Claude
“Endothelin receptor ET-A antagonist”ChEMBL 37, by rule
Other programs on EDNRA
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Bosentanrule | Johnson & Johnson | phase 4 | 37 |
| sparsentanrule | travere-therapeutics-inc | phase 4 | 9 |
| Atrasentanrule | Novartis | phase 3 | 15 |
| aprocitentanrule | Idorsia Pharmaceuticals | phase 3 | 14 |
Studies
All 23 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07404137Renal Insufficiency, Chronic · United States | 1 | Completed | Apr 2, 2026 | 26 |
| NCT06942910Kidney Diseases · Russia | 2 | Active, not recruiting | Sep 26, 2026 | 224 |
| NCT06715670Liver Cirrhosis · United States | 1 | Completed | Feb 28, 2025 | 30 |
| NCT06269484Liver Cirrhosis · United States, Australia, Belgium and more | 2 | Completed | Dec 11, 2024 | 73 |
| NCT06087835Kidney Diseases · United States, Argentina, Australia and more | 3 | Active, not recruiting | Feb 18, 2027 | 1,835 |
| NCT05516498Liver Cirrhosis · United States, Australia, Austria and more | 2 | Terminated | May 22, 2025 | 205 |
| NCT05505162Renal Insufficiency, Chronic · United States | 1 | Completed | Jan 10, 2023 | 24 |
| NCT05112419Renal Insufficiency · Bulgaria | 1 | Completed | Dec 15, 2021 | 12 |
| NCT04991571Renal Insufficiency, Chronic · United States | 1 | Completed | Oct 22, 2021 | 27 |
| NCT04724837Renal Insufficiency, Chronic · United States, Argentina, Australia and more | 2 | Completed | Jun 1, 2023 | 542 |
| NCT00997945Advanced Solid Malignancies · China | 1 | Completed | Sep 2010 | 15 |
| NCT00929162Neoplasms · Germany, Italy | 2 | Terminated | Jun 2011 | 120 |
| NCT00745875Carcinoma, Non-Small-Cell Lung · Bulgaria, Czech Republic, France and more | 2 | Completed | Jan 2010 | 66 |
| NCT00713791Healthy · United States | 1 | Completed | 20 | |
| NCT00710047Healthy Volunteers · United Kingdom | 1 | Completed | Aug 2008 | 30 |
| NCT00709553Healthy · Germany | 1 | Completed | Aug 2008 | 12 |
| NCT00672581Hepatic Impairment · Czech Republic | 1 | Completed | 32 | |
| NCT00626548Prostatic Neoplasms · United States, Argentina, Australia and more | 3 | Terminated | Jan 2011 | 2,577 |
| NCT00617669Prostatic Neoplasms · United States, Argentina, Australia and more | 3 | Completed | May 2011 | 1,494 |
| NCT00554229Prostatic Neoplasms · United States, Argentina, Australia and more | 3 | Completed | Jul 2010 | 896 |
| NCT00314782Prostatic Neoplasms · United States, Germany, United Kingdom | 1 | Completed | Mar 2008 | 44 |
| NCT00090363Prostatic Neoplasms · United States, Australia, Belgium and more | 2 | Completed | Dec 2008 | 447 |
| NCT00055471Prostatic Neoplasms · United States | 2 | Completed | Oct 2005 | 22 |
How it is read
Names in the registry
- “ZD4054”, 11 entries
- “Zibotentan”, 4 entries
- “Zibotentan/Dapagliflozin”, 2 entries
- “ZD4054 (Zibotentan)”, 2 entries
- “ZD4054 15 mg”, 2 entries
Conditions, from the studies’ own filings
- Prostatic Neoplasms, 6 studies
- Renal Insufficiency, Chronic, 4 studies
- Liver Cirrhosis, 3 studies
- Kidney Diseases, 2 studies
- Renal Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.